Pharmerging

Global Market Trajectory & Analytics

MCP16682

EXECUTIVE ENGAGEMENTS

POOL

14103
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

1692
Interactions with Platform & by Email

PARTICIPANTS

423
Unique # Participated

VALIDATIONS

89
Responses Validated*

COMPANIES

22
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

36

PAGES

88

EDITION

9

PRICE

USD 4950

CODE

MCP16682


COMPETITIVE METRICS

COMPANY

D S N T

% *

Abbott Laboratories, Inc.

AbbVie, Inc.

Alexion Pharmaceuticals, Inc.

Allergan PLC

Amgen, Inc.

Aspen Pharmacare Holdings Ltd.

Astellas Pharma, Inc.

AstraZeneca PLC

Baxter International, Inc.

Bayer AG

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Pharmerging estimated at US$817.6 Million in the year 2020, is projected to reach a revised size of US$1.6 Billion by 2027, growing at aCAGR of 9.9% over the period 2020-2027. Pharmaceutical, one of the segments analyzed in the report, is projected to record 8.4% CAGR and reach US$960.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Healthcare segment is readjusted to a revised 12.5% CAGR for the next 7-year period.
The Pharmerging market in the U.S. is estimated at US$242.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$274.5 Million by the year 2027 trailing a CAGR of 9.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.9% and 8.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

SELECT PLAYERS

Abbott Laboratories; AbbVie, Inc.; Alexion Pharmaceuticals, Inc.; Allergan PLC; Amgen, Inc.; Aspen Pharmacare Holdings Ltd.; Astellas Pharma, Inc.; AstraZeneca PLC; Baxter International, Inc.; Bayer AG; Biogen, Inc.; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Celgene Corporation; CSL Behring; Daiichi Sankyo Co., Ltd.; Eisai Co., Ltd.; Eli Lilly and Company; Endo International PLC; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Grifols SA; H. Lundbeck A/S; Hospira, Inc.; Johnson & Johnson; Kyowa Hakko Kirin Co., Ltd.; Mallinckrodt Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Mylan Pharmaceutical Pvt. Ltd.; Novartis AG; Novo Nordisk A/S; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Sanofi SA; Shire PLC; Stada Arzneimittel AG; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd.; UCB SA

SEGMENTS

» Product (Pharmaceutical, Healthcare)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Pharmerging Market to Grow Steadily, Driven by Rapid Growth of the Pharma Sector
Table: Worldwide Pharmaceutical Market Growth Projections by Regional Group: 2018 and 2022
Table: Breakdown of Growth Percentage and Spending in Billion USD for Pharmerging Markets by Country: 2007-2022
Pharmaceutical Segment to Register Strong Growth
Table: Total Spending on Medicines (in Billion USD) in Select Emerging Pharmaceutical Markets: 2023
Table: Healthcare Market in Tier I Pharmerging Region (USD Billion) by Product: 2014-2025
Asia-Pacific Region to Retain Top Slot
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Growing Geriatric Population to Bode Well for Market Growth
Table: Total Breakdown of People Aged Over 60 by Development Groups: 1980 to 2050
Increase in Patient Numbers to Support Market Growth
Table: Top Therapeutic Areas by Spending (Billion USD) in Pharmerging Markets: 2018
Table: Select Therapy Areas Spending (Billion USD) in Pharmerging Markets: 2020
Increasing Preference for Generics to Spur Market Expansion
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Pharmerging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Pharmerging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
World Current & Future Analysis for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Healthcare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Healthcare by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027
CANADA
Canada Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027
JAPAN
Japan Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027
CHINA
China Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027
EUROPE
Europe Current & Future Analysis for Pharmerging by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Pharmerging by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
Europe Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027
FRANCE
France Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027
GERMANY
Germany Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027
ITALY
Italy Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027
Total Companies Profiled: 22

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com